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IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disease 
characterized by elevation of serum IgG4 level as well as infiltration of IgG4+ plasma 
cells in various affected organs. The etiology of IgG4-RD is still not fully understood. 
Since IgG4-RD is more prevalent in the elderly, aging in itself is considered to be an 
important risk factor of IgG4-RD. However, the relationship between the pathogenesis 
of IgG4-RD and immunosenescence remains unknown. To clarify age-related features 
underlying IgG4-RD, we focused on T follicular regulatory (Tfr) cells, which share 
forkhead box P3 with regulatory T cells, since the percentage of Tfr cells is known to 
depend on age. Studies of blood specimens from patients with IgG4-RD and from 
healthy volunteers demonstrated a marked elevation of circulating Tfr (cTfr) cells in 
patients with IgG4-RD. Moreover, the percentage of cTfr cells was significantly 
correlated with various clinical parameters including the level of serum IgG4 and the 
number of involved organs in IgG4-RD patients. The percentages of tonsillar and blood 
Tfr cells were increased with aging in healthy volunteers, whereas the suppressive effect 
of cTfr cells on B cell function in elderly subjects was impaired in comparison with that 
in young subjects due to a defect in the production of a regulatory cytokine, IL-10. 
Given that the number of IL-10-producing cTfr cells in IgG4-RD patients was markedly 
4 
 
increased compared with that in healthy elderly subjects, these findings suggest that an 
abnormal aging process of Tfr cells may be related to the pathogenesis of IgG4-RD. 
 
1. Introduction 
IgG4-related disease (IgG4-RD) is characterized by elevation of serum IgG4 
level and persistent fibroinflammation in an involved organ or involved organs such as 
the lacrimal glands, salivary glands, lymph nodes, pancreas, retroperitoneum, and lungs 
[1]. The main histopathological findings of the involved organs in IgG4-RD are marked 
infiltration of B cells and plasma cells producing IgG4, storiform fibrosis formed by 
spindle cells resembling fibroblasts, and obliterative phlebitis [1]. Additional 
pathological features of IgG4-RD are a dense lymphoplasmacytic infiltrate and the 
formation of ectopic germinal centers (GCs) where lymphoplasmacytes promote the 
production of IgG4 at an unusually high level. In general, systemic administration of 
glucocorticoids is the first line of therapy for IgG4-RD, though recent studies have 
shown that biologics such as rituximab, which is an anti-CD20 antibody that depletes B 
cells, and abatacept, which is an anti-CTLA-4 antibody that inactivates T cells, are quite 
effective even in recurrent cases as well as cases that are refractory to steroid therapy 
[2,3]. In addition, a recent study showed that abundant T follicular helper (Tfh) cells are 
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localized in lesions of IgG4-RD [4]. These findings suggest that uncontrollable GC 
responses underlie the pathogenesis of IgG4-RD.  
 In collaboration with Tfh cells, T follicular regulatory (Tfr) cells, a specialized 
CD4+ T cell subset, participate in the control of GC formation and class-switch 
recombination of B cells [5-7]. Tfr cells present CXCR5, which is also shared by B cells 
and Tfh cells. Moreover, they are regulated by B-cell lymphoma 6 (BCL6), 
programmed cell death 1 (PD-1), and inducible T-cell co-stimulator (ICOS) as well as 
forkhead box P3 (Foxp3), which is shared by regulatory T (Treg) cells [6,8]. To exert 
GC responses, Tfr cells produce IL-10 and TGF-β for the direct regulation of B cells 
and Tfh cells. Of note, IL-10 acts as a critical cytokine not only for a suppressive effect 
against immune cells but also for the class-switch recombination of IgG4 and for the 
promotion of GC responses [7,9,10]. However, the pathological significance of Tfr cells 
in IgG4-RD is not fully understood.  
It is well recognized that circulating Tfh (cTfh) cells in elderly adults have a 
lower capacity to help B cells than those in young adults with accompanying increased 
expression of PD-1 and decreased expression of ICOS [11]. Other studies have further 
shown an increased level of Foxp3+ Treg cells in aged humans and mice [12,13]. 
Therefore, the immune system undergoes striking aging-related changes, which 
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eventually proceed to a state of so-called immunosenescence [14]. In aged individuals, 
immunosenescence preferentially leads to inability to protect against infections and also 
predisposes the individuals to autoimmune and allergic disorders and even to 
malignancies [14]. Since one of the common clinical characteristics of IgG4-RD is a 
higher prevalence in the elderly, a possible relationship between immunosenescence and 
the pathogenesis of IgG4-RD has been suggested. Nonetheless, aging-related 
physiological changes of Tfr cells in IgG4-RD remain elusive.  
In the present study, we performed experiments using clinical specimens to 
address the question of whether Tfr cells have a role in the pathogenesis of IgG4-RD. 
The results showed that the numbers of Tfr cells in blood and submandibular glands 
(SMGs) from patients with IgG4-RD were significantly increased compared with those 
in peripheral blood and tonsils from healthy volunteers. The percentage of Tfr cells was 
positively correlated with clinical parameters including serum level of IgG4 and number 
of involved organs in IgG4-RD patients. We also found that, although tonsillar and 
circulating Tfr (cTfr) cells increased with aging, suppressive functions of Tfr cells from 
elderly subjects were impaired due to a decrease in their IL-10 production compared 
with the suppressive functions of Tfr cells from young subjects. Interestingly, the 
number of IL-10-producing cTfr cells in IgG4-RD patients was increased compared 
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with that in healthy elderly subjects. Collectively, the findings provide a novel insight 
into the role of Tfr cells in the pathogenesis of an aging-related disease, IgG4-RD.  
 
2. Materials and methods 
2.1. Study populations and clinical specimens 
The characteristics of patients with IgG4-RD (n = 49) and age-matched healthy 
volunteers (for Figs. 1 and 2, n = 53) are summarized in Supplementary Table S1. The 
involved organs in patients with IgG4-RD are also summarized in Supplementary Table 
S2. Diagnosis of IgG4-RD was performed according to the 2011 comprehensive 
IgG4-RD diagnostic criteria [15]. Blood specimens were collected from patients with 
IgG4-RD and analyzed prior to the entrance to treatment protocols as previously 
described [16]. Tissues of the SMGs and palatine tonsils were obtained from 21 patients 
with IgG4-RD (age of donors ranging from 10 to 66 years old) and from 41 patients 
with tonsillar hypertrophy (n = 14, age of donors ranging from 3 to 46 years old) or 
recurrent tonsillitis (n = 27, age of donors ranging from 10 to 66 years old) for diagnosis 
or treatment at Sapporo Medical University Hospital. To examine Tfr cells and Treg 
cells in different age groups of healthy volunteers, blood specimens were obtained from 
53 subjects (for Figs. 3 and 4, age of healthy donors ranging from 4 to 89 years old). 
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None of the healthy volunteers had abnormal physical or chest X-ray findings, and 
results of all blood tests were normal. Written informed consent was obtained in all 
cases according to the Declaration of Helsinki. All of the protocols were approved by 
the institutional review boards of Sapporo Medical University Hospital. 
 
2.2. Reagents  
Anti-human monoclonal antibodies (mAbs) including anti-CD3-APC (UCHT1), 
anti-CD4-APC-Cy7 (RPA-T4), anti-PD-1-PE (EH12.1), anti-PD-1-PE-Cy7 (EH12.1), 
anti-PD-1-BV421 (EH12.1), anti-CXCR5-PerCP-Cy5.5 (RF8B2), anti-CD25-FITC 
(M-A251), anti-CD127-PE-Cy7 (HIL-7R-M21), anti-CD127-BV421 (HIL-7R-M21), 
and anti-ICOS-BV421 (DX29) were purchased from BD Biosciences (Franklin Lakes, 
NJ, USA). An anti-Foxp3-eFluor 450 mAb (PCH101) was obtained from eBioscience 
(San Diego, CA, USA). Anti-CD3 (OKT3) and anti-CD28 (15E8) mAbs were 
purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). An anti-IL-10 (23738) 
mAb was obtained from R&D Systems (Minneapolis, MN, USA).  
 
2.3. Flow cytometric analysis and cell sorting  
Peripheral blood mononuclear cells (PBMCs) were isolated from blood 
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specimens by centrifugation over a discontinuous density gradient (Lympholyte-H, 
Cedarlane; Burlington, ON, Canada). Tissue samples of tonsils and SMGs were 
mechanically disrupted into single lymphocyte suspensions for flow cytometry and cell 
sorting. Cell staining using cell surface markers was performed as previously described 
[4]. Intracellular staining for Foxp3 was performed with Foxp3/Transcription Factor 
Staining Buffer Set (Thermo Fisher Scientific; Waltham, MA, USA) as described in the 
protocol of the manufacturer. Samples were then analyzed using FACSCanto II (BD 
Biosciences). All data were analyzed using FACSDiva software (BD Biosciences) and 
FlowJo software (BD Biosciences). To isolate human Tfh cells and Tfr cells from tonsils 
or PBMCs, CD4+ T cells were enriched by using a MagniSort human CD4 T cell 
enrichment kit (Thermo Fisher Scientific). CD4+ T cells were stained with surface 
markers (CD3, CD4, CD25, CD127, CXCR5, and PD-1) for their detection. 
CD3+CD4+CD25-CD127+CXCR5+PD-1+ and CD3+CD4+CD25+CD127-CXCR5+PD-1+ 
cells were defined as Tfh and Tfr cells, respectively [17], and were sorted with 
FACSAria II (BD Biosciences). . The purity of FACS-sorted cells was more than 95% 
after validation with reanalysis using FACSCanto II. B cells were isolated from tonsils 
or PBMCs using a MagniSort human B cell enrichment kit (Thermo Fisher Scientific). 




2.4. T cell and B cell coculture assays 
Sorted Tfh cells (CD3+CD4+CD25-CD127+CXCR5+PD-1+ cells) in the 
presence or absence of Tfr cells (CD3+CD4+CD25+CD127-CXCR5+PD-1+ cells) from 
tonsils were plated with autologous or allogeneic blood B cells (CD3-CD19+ cells) from 
healthy volunteers in a 1:1:1 ratio (1 x 105 cells each) and cocultured for 10 days in 
AIM-V serum-free medium (Thermo Fisher Scientific) supplied with 10 µg/ml 
anti-CD3 Ab and 10 µg/ml anti-CD28 Ab (Miltenyi Biotec). Then culture supernatants 
were analyzed in triplicate by ELISA. For a suppression assay, 5 ug/ml anti-IL-10 mAb 
was added to the coculture medium. 
 
2.5. Measurement of immunoglobulins  
Concentrations of IgG in cell-free culture supernatants were analyzed in 
triplicate with ELISAs as described in the manufacturer’s protocol (Bethyl Laboratories; 
Montgomery, TX, USA). The detection limit of IgG is 7.8 ng/ml. 
 
2.6. RNA isolation and quantitative real-time PCR  
For quantitative real-time PCR analysis, total RNA extracted by TRIzol reagent 
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(Thermo Fisher Scientific) was reverse-transcribed using a MultiScribe MuLV (Thermo 
Fisher Scientific). Quantitative real-time PCR was performed with a LightCycler 
real-time PCR system (F. Hoffmann-La Roche; Basel, Switzerland) using TaqMan gene 
expression assay (Thermo Fisher Scientific) and SYBR Green (Takara Bio Inc.; Shiga, 
Japan). For the TaqMan-based detection system, the amount of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used to standardize 
the amount of IL10 (Hs00174086) and TGFB1 (Hs00171257) mRNAs. Sequences of 
the primer set for SYBR Green-based detection were designed and used in this study 
(Supplementary Table S3). The ∆∆CT method was used to calculate the relative mRNA 
expression of triplicate specimens.  
 
2.7. IL-10 secretion assay 
To detect IL-10 production, lymphocytes from tonsils and blood specimens 
were assessed using an IL-10 secretion assay kit (Miltenyi Biotec) following the 
manufacturer’s protocol. IL-10-producing cells were analyzed by FACSCantoII.  
 
2.8. Statistical analysis 
All data are shown as mean ± SD. Significant differences between any two 
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groups were determined by using the Mann-Whitney U test. Multiple group 
comparisons were analyzed with the Kruskal-Wallis test. Correlations were determined 




3.1. Blood and tissue Tfr cells are increased in IgG4-RD. 
Previous studies have shown that activated Tfh cells were increased in 
peripheral blood from patients with IgG4-RD and that their percentage was significantly 
correlated with clinical parameters [4,18]. To address the role of Tfr cells in IgG4-RD, 
we examined cTfr cells and cTfh cells as well as other immune cells in blood from 
patients with IgG4-RD. Initially, we analyzed CD3+CD4+CD25+CD127-CXCR5+PD-1+ 
cells and CD3+CD4+CD25-CD127+CXCR5+PD-1+ cells as Tfr cells (CD25+CD127- Tfr 
cells) and Tfh cells (CD25-CD127+ Tfh cells), respectively [17]. As shown in Figs. 
1A-C and Supplementary Table S4, the percentages and numbers of CD25+CD127- cTfr 
cells and CD25-CD127+ cTfh cells were significantly increased in blood from patients 
with IgG4-RD compared with those in blood from age-matched healthy volunteers. To 
know the specificity of such cell surface markers to detect Tfr cells, we also analyzed 
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CD3+CD4+CD25+CXCR5+PD-1+Foxp3+ cells (Foxp3+ cTfr cells) and examined the 
correlation between the absolute numbers of CD25+CD127- cTfr cells and Foxp3+ cTfr 
cells. As expected, we found a clear correlation (r = 0.8061 and p = 0.0072) between the 
two phenotypes of cTfr cells (Fig. 1D). Indeed, the percentage and number of Foxp3+ 
cTfr cells were significantly increased in blood from patients with IgG4-RD (Fig. 1E 
and Supplementary Table S5). In addition, we found that the percentages of 
CD25+CD127- Tfr cells and Foxp3+ Tfr cells were significantly increased in affected 
tissues of SMGs from patients with IgG4-related dacryoadenitis and sialadenitis 
(IgG4-DS) compared with those in tonsils from patients with tonsillar hypertrophy as 
controls (Fig. 1F). Taken together, the results showed that Tfr cells were markedly 
increased in both peripheral blood and involved tissues in IgG4-RD patients. 
 
3.2. Circulating Tfr cells are positively correlated with clinical parameters in 
IgG4-RD. 
We next studied the relationships between the percentage of cTfr cells and 
various clinical parameters in IgG4-RD. Interestingly, the percentage of cTfr cells was 
significantly correlated with serum levels of IgG4 (r = 0.5008 and p = 0.0176) and 
IgG4/IgG (r = 0.5246 and p = 0.0122) but not with total IgG (r = 0.3597 and p = 
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0.1001), IgM (r = -0.0745 and p = 0.7549), IgA (r = 0.0451 and p = 0.8502), or IgE (r = 
-0.0677 and p = 0.7768) (Fig. 2A). We further analyzed the relationships of the 
percentage of cTfr cells with the number of involved organs, serum level of soluble IL-2 
receptor (sIL-2R) as an activation marker of T cells, and serum levels of complement 
components (C3 and C4) that are involved in autoimmune diseases such as systemic 
lupus erythematosus [19]. The percentage of cTfr cells was also significantly correlated 
with the number of organs involved (r = 0.4510 and p = 0.0459) and with the serum 
level of soluble IL-2 receptor (r = 0.6130 and p = 0.0031), but we failed to find any 
significant correlation of cTfr cells with C3 (r = -0.1997 and p = 0.4123) and C4 (r = 
-0.2491 and p = 0.3037) (Fig. 2B and Supplementary Fig. S1). Therefore, these findings 
suggest that the elevated level of cTfr cells is clearly related to the levels of factors 
defining the clinical status of IgG4-RD. 
It is well known that Tfr cells generally have a high capacity to produce IL-10 
[6] and that the expression level of IL-10 in affected tissues as well as the serum level of 
IL-10 are profoundly increased in IgG4-RD [7,20,21]. Moreover, accumulating 
evidence suggests that IL-10 facilitates class-switch recombination of IgG4 in B cells 
[9,10]. Based on such reported evidence about IL-10, we further investigated the 
functional capacity of cTfr cells to produce IL-10 in IgG4-RD. Although the 
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IL-10-producing capacity of cTfr cells in IgG4-RD patients was comparable to that of 
cTfr cells in age-matched healthy volunteers, the absolute number of IL-10-producing 
Tfr cells in IgG4-RD patients was significantly increased compared with that in 
age-matched healthy volunteers (Fig. 2C). These results suggest that IL-10 produced by 
Tfr cells, which are increased in blood of patients with IgG4-RD, possibly influences 
IgG4-specific class-switch recombination of B cells in the involved lesions.  
 
3.3. Tfr cells increase with aging.  
Our findings indicated that the increased level of Tfr cells, which could 
normally produce IL-10, might be related to the pathogenesis of IgG4-RD. IgG4-RD is 
well recognized as a prevalent disorder that frequently occurs in elderly persons. 
Therefore, we were interested in an age-associated natural course of Tfr cells. To know 
this, characteristic alterations of Foxp3+ Tfr cells 
(CD3+CD4+CD25+CXCR5+PD-1+Foxp3+ cells) and Treg cells 
(CD3+CD4+CD25+Foxp3+ cells) were investigated in peripheral blood of healthy 
volunteers of various ages. It was found that the percentages of cTfr cells and cTreg 
cells increased with advance of age, especially at ages with a high prevalence of 
IgG4-RD (Figs. 3A and B). In accordance with the evidence that Tfr cells originate from 
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Treg cells, the percentage of cTfr cells is likely to be in parallel with the percentage of 
cTreg cells throughout life [22,23]. We next examined Tfr cells and Treg cells residing 
in tonsils from patients who underwent tonsillectomy due to simple hypertrophy. In 
accordance with the results obtained from blood specimens, it was found that Tfr cells 
and Treg cells in tonsils increased with aging (Figs. 3C and D). Collectively, the results 
suggest that Tfr cells tend to increase in blood and peripheral tissues of aged individuals 
as a natural property. In contrast, the percentage of activated Tfh cells in tonsils 
decreased with advance of age (Supplementary Fig. S2), while total Tfh cells in blood 
have been shown to gradually increase with aging [24].  
 
3.4. Suppressive function of Tfr cells is impaired in elderly subjects.  
We further investigated a possible functional alteration of Tfr cells during 
senescence. To determine age-related functional differences in Tfr cells, we analyzed 
two age groups of healthy individuals: a young group (less than 19 years old) and an 
elderly group (over 40 years old). Prior to investigation of Tfr cells, we confirmed a 
high level of expression of FOXP3 transcripts in sorted Tfr cells (CD25+CD127- Tfr 
cells) compared with that in sorted Tfh cells (CD25-CD127+ Tfh cells; Supplementary 
Fig. S3). When tonsillar lymphocytes were examined, the percentage of CD25+CD127- 
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Tfr cells in elderly subjects was increased compared with that in young subjects (Figs. 
4A and B). To analyze the suppressive function of such Tfr cells, we performed a 
functional assay of Tfr cells using a coculture system in which autologous lymphocytes 
including Tfh cells and B cells were cultured in the presence or absence of Tfr cells for 
10 days and then the concentrations of IgG in the supernatants were measured by 
ELISA (Fig. 4C). The concentrations of IgG in the supernatants without Tfr cells of 
young subjects were comparable to those of elderly subjects, whereas the concentrations 
of IgG with Tfr cells of young subjects were significantly lower than those of elderly 
subjects (Figs. 4D and E). These results suggest that Tfr cells from young subjects have 
a high suppressive potential in terms of IgG production compared with Tfr cells from 
elderly subjects. Results similar to those of the coculture experiments were obtained by 
using tonsillar lymphocytes including autologous Tfr cells and Tfh cells from young and 
elderly subjects in combination with allogeneic B cells (data not shown). Collectively, 
the results indicate that Tfr cells with a defective suppressive function increase with 
advance of age.  
 




To determine the mechanism by which the suppressive function of Tfr cells in 
elderly subjects is attenuated, we examined the expression levels of gene transcripts 
related to immune suppression. Quantitative real-time PCR analyses showed that Tfr 
cells in tonsils from elderly subjects had lower levels of transcripts encoding IL10 than 
did those in tonsils from young subjects (Fig. 5A), while the amounts of transcripts 
encoding TGFΒ1, CTLA4, and glucocorticoid-induced TNFR-related protein (GITR, 
TNFRSF18) were comparable to those in tonsils from young subjects (Figs. 5B-D). We 
further determined the percentage of IL-10-producing Tfr cells by an IL-10 secretion 
assay. As shown in Figs. 5E and F, the percentages of IL-10-producing Tfr cells were 
significantly decreased in tonsils and peripheral blood from elderly subjects compared 
with those in tonsils and peripheral blood from young subjects. To clarify the role of 
IL-10 produced by Tfr cells, we performed coculture experiments and examined IgG 
production in the presence of a blocking antibody specific to IL-10 (Fig. 5G). As shown 
in Fig. 5H, blocking with an anti-IL-10 antibody restored IgG production by Tfr cells 
from young subjects. However, blockade of IL-10 production did not affect the 
regulation of IgG production by Tfr cells from elderly subjects (Fig. 5I). These results 
suggest that IL-10 is one of the essential factors that exert the suppressive activity of Tfr 
cells in young individuals and that secretion of IL-10 by Tfr cells decreases with 
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advance of age.  
 
4. Discussion 
In this study, we performed a comprehensive analysis of circulating CD4+ T 
cells and for the first time showed the possible involvement of Tfr cells in the 
pathogenesis of IgG4-RD. Tfr cells have a critical function to control the magnitude of 
GC responses by modulating Tfh cells and B cells [6]. Moreover, recent studies have 
revealed that IL-10 produced from Tfr cells promotes the germinal center response [7], 
which means that Tfr cells have not only a suppressive function but also a stimulatory 
function. Although the mechanism by which IgG4 production from B cells is morbidly 
enhanced in lesions of IgG4-RD remains unclear, our findings suggest that an increase 
in Tfr cells in blood and lesions of IgG4-RD is associated with the immunological 
mechanisms of IgG4-RD. 
As shown in Fig. 2A, the percentage of Tfr cells in IgG4-RD was significantly 
correlated with the serum level of IgG4 but not with the levels of other immunoglobulin 
subclasses. In addition, the absolute number of IL-10-producing Tfr cells in IgG4-RD 
patients was significantly increased compared with that in age-matched healthy 
volunteers (Fig. 2C). We and another group recently reported that activated Tfh cells 
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expressing high levels of BCL6 and PD-1 are remarkably accumulated in the lesions of 
IgG4-RD and that Tfh cells in patients with IgG4-RD more efficiently facilitated B cell 
proliferation as well as differentiation of naive B cells into plasmablasts/plasma cells, 
resulting in increased secretion of IgG4 [4,25]. Other studies showed that Tfr cells have 
the capacity to control the proliferation of Tfh cells [26] and that the proliferative 
activity of GC B cells depends on IL-10 secreted by Tfr cells [7]. Moreover, IL-10 
facilitates class-switch recombination of IgG4 in B cells [9,10]. From the results of 
those previous studies and results of our study shown in Figs. 1 and 2, an increased 
number of Tfr cells might lead to the activation of Tfh cells and B cells, and an 
increased number of IL-10-producing Tfr cells is potentially involved in IgG4-specific 
class-switch recombination in a lesion of IgG4-RD. The precise mechanisms by which 
Tfr cells induce proliferation of activated Tfh cells and the mechanism of IgG4-specific 
class-switch recombination in a lesion of IgG4-RD are still unclear but warrant 
examination. Moreover, although the reason why Tfr cells in blood from patients with 
IgG4-RD were increased compared with those in age-matched healthy volunteers (Fig. 
1) is not known, it is possible that the increased numbers of circulating and lesional Tfr 
cells in IgG4-RD reflect a compensatory change so as to suppress abnormal immune 
responses. Further studies are needed in order to clarify the mechanisms of 
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accumulation of Tfr cells in IgG4-RD. Collectively, the results support the unique 
immunological environment in IgG4-RD, in which there is an increased number of Tfr 
cells and activated Tfh cells, probably underlying the pathogenesis of IgG4-RD. 
Patients with autoimmune diseases such as systemic lupus erythematous and 
primary biliary cirrhosis show a lower Tfr/Tfh ratio in blood lymphocytes, which is 
probably associated with the production of self-specific antibodies [27,28]. Thus, it 
would be worthwhile to focus on the relationship between Tfr cells and Tfh cells as a 
new clue to elucidate the pathogenesis of immune disorders. Our results showed that 
there was no significant difference in the Tfr/Tfh ratio in blood lymphocytes between 
healthy subjects and IgG4-RD patients (Supplementary Fig. S4). A more recent study on 
autoimmune pancreatitis of IgG4-RD revealed for the first time an autoantibody against 
one of the extracellular matrix proteins [29], suggesting a certain autoimmune 
mechanism underlying IgG4-RD. The manner in which B cells are made to produce 
autoantibodies in IgG4-RD may be unique because the characteristics of Tfr cells and 
Tfh cells and the relationship between them in IgG4-RD are likely to be different from 
those in typical autoimmune diseases. 
We showed that the percentages of tonsillar and blood Tfr cells increased with 
aging in healthy volunteers, whereas the suppressive effect of blood Tfr cells on B cell 
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function in elderly subjects was impaired in comparison with that in young subjects due 
to a defect in the production of IL-10 (Figs. 4 and 5). On the other hand, the percentage 
of activated Tfh cells also decreased with advance of age (Supplementary Fig. S2). A 
recent study in mice showing that an increase in suppressive Tfr cells combined with 
impaired function of aged Tfh cells resulted in reduced T-cell-dependent antibody 
responses in aged mice [30] supports our findings. Regarding change in suppressive 
function of Tfr cells with aging we have to consider not only functional defects of Tfr 
cells, but also those of target cells such as activated Tfh cells and B cells. Little has been 
reported regarding aging-related physiological changes of Tfr cell function in humans. 
Therefore, this study provides important information on such changes.   
In conclusion, this study provides novel and important information on the 
functional significance of Tfr cells and IL-10 produced by Tfr cells in the pathogenesis 
of IgG4-RD. Focusing on the regulation of Tfr cells and activated Tfh cells may be an 
effective strategy for preventing the development of IgG4-RD. In this study, we showed 
stimulatory (Figs. 1 and 2) and suppressive functions (Figs. 4 and 5) of Tfr cells. Owing 
to the limitation of clinical specimens, we could not examine the suppressive function 
of Tfr cells in IgG4-RD and the stimulatory function of Tfr cells in healthy volunteers. 
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Figure legends   
Fig. 1. Blood and tissue Tfr cells are increased in IgG4-RD.  
(A) Representative FACS profiles indicating CD25+CD127- Tfr cells and CD25-CD127+ 
Tfh cells in IgG4-RD patients and healthy volunteers. Plots were pregated on 
CD3+CD4+CXCR5+PD-1+ cells and examined by the levels of CD25 and CD127. 
Numbers indicate percentage of cells in the gate.  
(B) Percentages of circulating CD25+CD127- Tfr (CD25+CD127- cTfr; 
CD3+CD4+CD25+CD127-CXCR5+PD-1+) cells in CD4+ cells (left) and absolute 
numbers of CD25+CD127- cTfr cells (right) from patients with IgG4-RD (n = 22) and 
healthy volunteers (n = 23) are shown.  
(C) Percentages of circulating CD25-CD127+ Tfh (CD25-CD127+ cTfh; 
CD3+CD4+CD25-CD127+CXCR5+PD-1+) cells in CD4+ cells (left) and absolute 
numbers of CD25-CD127+ cTfh cells (right) from patients with IgG4-RD (n = 22) and 
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healthy volunteers (n = 23) are shown.  
(D) Scatter plots demonstrating the relationships between absolute number of 
CD25+CD127- cTfr cells and absolute number of Foxp3+ cTfr cells in IgG4-RD cases (n 
= 10).  
(E) Percentages of Foxp3+ cTfr cells (CD3+CD4+CD25+CXCR5+PD-1+Foxp3+ cells) in 
CD4+ cells (left) and absolute numbers of Foxp3+ cTfr cells (right) from patients with 
IgG4-RD (n = 35) and healthy volunteers (n = 22) are shown.  
(F) Percentages of CD25+CD127- Tfr cells in CD4+ cells (n = 9 in each group, left) and 
Foxp3+ Tfr cells (n = 24 in each group, right) in submandibular glands (SMGs) from 
patients with IgG4-related dacryoadenitis and sialadenitis (IgG4-DS) and in tonsils are 
shown. Horizontal lines and error bars indicate mean and SD, respectively. *; p < 0.05, 
***; p < 0.001, ****; p < 0.0001 by the Mann-Whitney U test.  
 
Fig. 2. Increased blood Tfr cells in IgG4-RD are positively correlated with clinical 
parameters. 
(A, B) Scatter plots demonstrating the relationships of circulating CD25+CD127- Tfr 
cells (CD25+CD127- cTfr cells) in CD4+ cells with serum IgG4, IgG4/IgG ratio, IgG, 
IgM, IgA, IgE (A), number of involved organs, and serum soluble IL-2 receptor 
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(sIL-2R) (B) in IgG4-RD cases (n = 20).  
(C) Graphs showing percentages (left) and absolute numbers (right) of IL-10-producing 
Tfr cells in blood from patients with IgG4-RD (n = 5) and healthy volunteers (n = 6). 
Horizontal lines and error bars indicate mean and SD, respectively. **; p < 0.01, ns 
indicating not significant by the Mann-Whitney U test.  
 
Fig. 3. Percentages of Tfr cells and Treg cells increase with advance of age. 
(A, B) Percentage of CXCR5+PD-1+ cells in regulatory T (Treg; CD25+Foxp3+) cells  
(A) and percentage of Treg cells in CD3+CD4+ cells (B) in blood from healthy 
volunteers are shown (n = 3-8 in each group).  
(C, D) Percentage of CXCR5+PD-1+ cells in Treg cells (C) and percentage of Treg cells 
in CD3+CD4+ cells (D) in tonsils are shown (n = 3 - 7 in each group).  
(A-D) Horizontal lines indicate mean, and statistical significance was determined using 
the Kruskal-Wallis test with 0-9-years-old age group v.s. each age group. *; p < 0.05, 
**; p < 0.01. 
 
Fig. 4. Suppressive function of Tfr cells is impaired in elderly subjects. 
(A) Representative FACS profiles indicating CD25+CD127- Tfr cells in young and 
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elderly subjects. Plots were pregated on CD3+CD4+CXCR5+PD-1+ cells and examined 
by the levels of CD25 and CD127. Numbers indicate percentage of cells in the gate.  
(B) Percentages of CD25+CD127- Tfr cells in CD3+CD4+CXCR5+PD-1+ cells in tonsils 
from young and elderly subjects are shown (n = 7 in each group).  
(C) Schematic representation of the suppression assay. Sorted CD25-CD127+ Tfh cells 
(1 x 105) and B cells (1 x 105) in tonsils from young and elderly subjects were 
cocultured with/without 1 x 105 autologous CD25+CD127- Tfr cells with stimulation by 
10 µg/ml anti-CD3 and 10 µg/ml anti-CD28 antibodies for 10 days.  
(D, E) ELISA determination of IgG (mg/ml) in supernatants after 10 days of in vitro 
coculture (D: young, E: elderly) performed as described in (C). Numbers indicate the 
ratio of IgG concentration in the supernatant from coculture of Tfr, Tfh, and B cells to 
that in the supernatant from coculture of Tfh and B cells. Representative data of three 
independent experiments are shown.  
(B, D, E) Horizontal lines and error bars indicate mean and SD, respectively. *; p < 0.05, 
**; p < 0.01, ns indicating not significant by the Mann-Whitney U test.  
 




(A-D) Graphs showing expression levels of IL10 (A), TGFB1 (B), CTLA4 (C), and 
TNFRSF18 (D) mRNA in tonsillar CD25+CD127- Tfr cells from young and elderly 
subjects (n = 4-5).  
(E, F) Graphs showing percentages of IL-10-producing cells in tonsillar (E) and blood 
(F) CD25+CD127- Tfr cells from young and elderly subjects (n = 6).  
(G) Schematic representation of the suppression assay. Sorted CD25-CD127+ Tfh cells 
(1 x 105) and B cells (1 x 105) in tonsils from young and elderly subjects were 
cocultured with/without 1 x 105 autologous CD25+CD127- Tfr cells with stimulation by 
10 µg/ml anti-CD3 and 10 µg/ml anti-CD28 antibodies and in the presence or absence 
of 5 μg/ml anti-IL-10 blocking antibody for 10 days.  
(H, I) ELISA determination of IgG (mg/ml) in supernatants after 10 days of in vitro 
coculture (D: young, E: elderly) performed as described in (G). Numbers indicate the 
ratio of IgG concentration in the supernatant from coculture of Tfr, Tfh, and B cells to 
that in the supernatant from coculture of Tfh and B cells. Representative data of three 
independent experiments are shown.  
(A-F, H, I) Horizontal lines and error bars indicate mean and SD, respectively. *; p < 













(n = 53) (n = 49) 
Age (years)  
55.4 ± 11.9 
(39-82) 
63.0 ± 11.2 






    mean ± SD 
(range) 
IgG (mg/dl)      
not available 
1959.3 ± 829.4 
(1145-4902) 
IgG4 (mg/dl)    
543.4 ± 481.8 
(147-2640) 
IgM (mg/dl)     
72.6 ± 43.6 
(24-224) 
IgA (mg/dl)     
203.9 ± 73.5 
(79-420) 
IgE (IU/ml)     




693.7 ± 344.1 
(243-1688) 




Supplementary Table S1. Characteristics of the subjects in this study. IgG4-RD, 
IgG4-related disease; sIL-2R, soluble IL-2 receptor. 
Organs Involved  Number % 
Submandibular gland 41 83.7  
Lacrimal gland  26 53.1  
Lymph node  16 32.7  
Pancreas  14 28.6  
Lung  11 22.4  
Parotid gland  10 20.4  
Kidney  6 12.2  
Prostate 3 6.1  
Thyroid  2 4.1  
Aorta 2 4.1  
Paranasal sinus 2 4.1  
Retroperitoneal fibrosis 1 2.0  
Spleen 1 2.0  
Sublingual gland 1 2.0  
 
 




Supplementary Table S3. RT-PCR primers used in this study. 
 
Gene Forward primer (5’ → 3’) Reverse primer (5’ → 3’) 
CTLA4 CTCAGCTGAACCTGGCTACC CTTCAGTCACCTGGCTGTCA 
FOXP3 CATGATCAGCCTCACACCAC CCACTTGCAGACACCATTTG 
TNFRSF18 GAGTGGGACTGCATGTGTGT AGCAGCAGTCTGTCCAAGGT 
GAPDH GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG 
  
Healthy IgG4-RD 
 (n = 23)  (n = 22) 
Age (years)  
47.3 ± 6.20 
(40-66) 
58.8 ± 12.1 






    means ± SD 
(range) 
IgG (mg/dl)      
not available 
1954.6 ± 621.9 
(1183-3423) 
IgG4 (mg/dl)    
562.3 ± 361.9 
(184-1500) 
IgM (mg/dl)     
77.7 ± 33.4 
(26-167) 
IgA (mg/dl)     
204.8 ± 84.4 
(79-420) 
IgE (IU/ml)     





702.9 ± 289.7 




Supplementary Table S4. Characteristics of the subjects in Fig. 1B. IgG4-RD, 
IgG4-related disease; sIL-2R, soluble IL-2 receptor. 
  
Healthy IgG4-RD 
 (n = 22)  (n = 35) 
Age (years)  
57.7 ± 12.6 
(39-82) 
64.0 ± 11.1 






    means ± SD 
(range) 
IgG (mg/dl)      
not available 
1937.7 ± 907.5 
(1145-4902) 
IgG4 (mg/dl)    
553.2 ± 539.5 
(147-2640) 
IgM (mg/dl)     
69.5 ± 42.0 
(24-222) 
IgA (mg/dl)     
198.2 ± 63.8 
(79-315) 
IgE (IU/ml)     




676.1 ± 323.9 
(297-1688) 




Supplementary Table S5. Characteristics of the subjects in Fig. 1E. IgG4-RD, 
IgG4-related disease; sIL-2R, soluble IL-2 receptor. 
